Bracco Imaging and NYU Langone Health Form Strategic Alliance to Advance Medical Imaging Innovation
Key Insights
Bracco Imaging (search) and NYU Langone Health signed a multi-year Master Research Agreement to accelerate development of advanced imaging technologies including MRI, CT, ultrasound and PET/CT.
The collaboration will focus on Photon-Counting Computed Tomography, targeted ultrasound, and artificial intelligence-enabled PET/CT and MRI image analysis to support precision medicine.
The partnership aims to enhance diagnostic performance, streamline clinical workflows, and facilitate translation of scientific discoveries into real-world healthcare applications.
Bracco Imaging (search) announced a strategic alliance with NYU Langone Health to advance innovation in medical imaging through a multi-year Master Research Agreement (MRA). The collaboration aims to accelerate the development and optimization of advanced imaging technologies by combining resources, scientific capabilities and complementary expertise to enhance clinical insights and improve patient management.
Partnership Focus Areas
The partnership will concentrate on key areas of diagnostic imaging, including Magnetic Resonance Imaging (MRI), Photon-Counting Computed Tomography (PCCT), targeted ultrasound, and artificial intelligence-enabled PET/CT and MRI image analysis. Through this collaboration, both parties aim to further support the advancement of precision medicine and enable more informed and timelier clinical decision-making.
The agreement is designed to foster closer interaction between research and clinical practice, facilitating the translation of scientific discoveries into real-world healthcare applications. Joint research activities will leverage NYU Langone Health's clinical and academic excellence alongside Bracco's longstanding expertise in contrast imaging and diagnostic solutions.
Leadership Perspectives
"The agreement reflects a shared commitment between the Bracco Group and NYU Langone Health to advance research and clinical innovation in medical imaging," said Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging (search). "NYU Langone Health is among the world's most respected leaders in radiology, with a proven history in translational research and an exceptional ability to combine clinical practice, advanced technologies, and academic expertise. By combining our respective strengths, we aim to further enhance diagnostic performance, streamline clinical workflows and ultimately generate meaningful impact for patients and healthcare systems."
Michael P. Recht, M.D., the Louis Marx Professor of Radiology and chair of the Department of Radiology at NYU Grossman School of Medicine (search), emphasized the importance of strategic collaborations in advancing diagnostic imaging. "Diagnostic imaging is advancing at a remarkable pace, and strategic collaborations are essential to progress," Recht said. "We are excited to build on NYU Langone Health's legacy of advances and to work with the Bracco Group toward breakthroughs in modalities central to precision medicine in terms of superior diagnostic accuracy and enhanced clinical decision-making."
Company Profiles
Bracco Imaging (search) is a global leader in diagnostic imaging, dedicated to improving people's lives by shaping the future of prevention and precision medicine. The company develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents (search) for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles (search) for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers (search) and novel PET imaging agents (search), alongside specialized medical devices and related services.
Since 1927, Bracco Imaging (search) has grown to more than 3,800 employees and now supports patients, healthcare professionals, and healthcare systems in over 100 countries. The company also operates Blue Earth Diagnostics, an indirect subsidiary focused on delivering innovative diagnostic solutions through positron emission tomography (PET) radiopharmaceuticals.
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation for four years in a row, and U.S. News & World Report recently ranked four of its clinical specialties No. 1 in the nation.
The health system offers a comprehensive range of medical services across seven inpatient locations, its Perlmutter Cancer Center (search), and more than 320 outpatient locations in the New York area and Florida. The system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.